Valuation: Monte Rosa Therapeutics, Inc.

Market Cap 1.22B 1.05B 978M 895M 1.68B 117B 1.7B 11.55B 4.51B 58.64B 4.58B 4.48B 194B P/E 2026 *
-8.8x
P/E 2027 * -7.54x
Enterprise Value 1.22B 1.05B 978M 895M 1.68B 117B 1.7B 11.55B 4.51B 58.64B 4.58B 4.48B 194B EV / Sales 2026 *
22.7x
EV / Sales 2027 * 21.4x
Free-Float
99.44%
Yield 2026 *
-
Yield 2027 * -
1 day-3.25%
1 week-7.74%
Current month-13.44%
1 month-37.91%
3 months-23.98%
6 months-26.70%
Current year-8.80%
1 week 14.17
Extreme 14.17
16.2
1 month 14.17
Extreme 14.17
23.65
Current year 13.69
Extreme 13.69
25.77
1 year 4.54
Extreme 4.54
25.77
3 years 2.44
Extreme 2.44
25.77
5 years 2.44
Extreme 2.44
45.56
10 years 2.44
Extreme 2.44
45.56
Manager TitleAgeSince
Chief Executive Officer 55 31/12/2019
Chief Tech/Sci/R&D Officer - 16/03/2026
Chief Operating Officer 54 28/02/2021
Director TitleAgeSince
Director/Board Member 55 31/12/2019
Director/Board Member 49 31/03/2020
Director/Board Member 57 31/05/2020
Date Insider Type Main position Quantity % Market Cap.
16/07/26 Sell

Chief Executive Officer

-9,500 0.0112%
15/07/26 Fiscal year

Chief Operating Officer

13,053 0.0155%
06/07/26 Fiscal year

Chief Technology Officer

18,000 0.0213%
Change 5-day change 1-year change 3-year change Capi.($)
-3.25%-7.74%+196.68%+123.79% 1.22B
+1.09%+5.26%+4.52%+23.38% 51.61B
-1.07%+2.82%+465.96%+570.70% 44.89B
+1.47%+9.79%+35.92%+20.21% 42.77B
+1.44%+7.77%+19.38%+84.65% 42.58B
-0.93%-4.33%+16.18%+55.82% 31.82B
+1.32%+7.30%+33.89%+148.53% 17.33B
-0.60%+1.93% - - 16.63B
+0.03%+3.41%+6.55%+29.84% 14.76B
+1.28%+5.41%+82.40%+46.13% 14.09B
Average +0.08%+3.22%+95.72%+122.56% 27.77B
Weighted average by Cap. +0.47%+4.66%+100.03%+141.30%

Financials

2026 *2027 *
Net sales 53.67M 45.97M 43.02M 39.38M 73.9M 5.14B 74.87M 508M 198M 2.58B 202M 197M 8.53B 57.07M 48.88M 45.74M 41.87M 78.58M 5.46B 79.61M 540M 211M 2.74B 214M 210M 9.07B
Net income -164M -141M -132M -120M -226M -15.71B -229M -1.55B -606M -7.89B -617M -603M -26.1B -201M -172M -161M -148M -277M -19.26B -281M -1.91B -743M -9.68B -756M -739M -32.01B
Net Debt - -
Logo Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Employees
173
Date Price Change Volume
21/08/26 US$14.30 -3.25% 969,159
20/08/26 US$14.78 -6.28% 1,021,633
19/08/26 US$15.77 +4.92% 1,070,233
18/08/26 US$15.03 -2.28% 1,131,845
17/08/26 US$15.38 -0.77% 815,979
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
14.30USD
Average target price
28.50USD
Spread / Average Target
+99.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLUE Stock